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espite advances over the past two decades in the
tolerability and safety of antidepressant treatment with
the development of the selective serotonin reuptake
inhibitors (SSRIs),serotonin norepinephrine reuptake
inhibitors (SNRIs),and other agents,antidepressant side
effects continue to pose considerable challenges to treat-
ment.Side effects sometimes exacerbate or masquerade
as residual depressive symptoms,and often precipitate
premature discontinuation or the use of subtherapeutic
doses of antidepressants. In the following review we
describe the scope of antidepressant side effects and their
impact on treatment adherence,methodological issues
concerning the study of side effects,and the most com-
mon side effects and approaches to management.
Anticipating,recognizing,and vigorously managing anti-
depressant side effects are crucial avenues for achieving
remission in depression as well as preventing relapse and
recurrence.
Prevalence and impact of side effects
Despite considerable improvements in side-effect pro-
files,antidepressants continue to be associated with a sig-
nificant burden of side effects that affect treatment
adherence and quality of life. Hu et al
1 studied 401
patients with depression who had recently been pre-
scribed an SSRI,and found that after 75 to 105 days of
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The safety and tolerability of antidepressants have
improved considerably over the past two decades.
Nevertheless, antidepressant side effects are still common
and problematic. The majority of patients treated with
contemporary agents experience one or more bothersome
side effects. These side effects often create barriers to
achieving depressive remission, as well as to preventing
relapse and recurrence. Clinicians tend to underestimate
the prevalence of side effects, and as many as one quar-
ter of patients discontinue their antidepressants because
of difficult-to-tolerate side effects; others may continue
on antidepressant therapy but experience diminished
quality of life related to troublesome side effects. This arti-
cle reviews the prevalence of side effects, the impact of
side effects on treatment adherence, and methodological
issues including the challenge of distinguishing side effects
from residual depressive symptoms, discontinuation
effects, and general medical problems. In addition, we
address the most common side effects such as sexual dys-
function, gastrointestinal problems, sleep disturbance,
apathy, and fatigue, and offer strategies for management
that may help patients achieve optimal response to phar-
macotherapy.    
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effect, and 55% experienced one or more bothersome
side effects.Interestingly,physicians appear to underes-
timate the rate of side effects with antidepressants.In a
survey of physicians and the patients to whom they had
prescribed SSRIs,
2 physicians underestimated the over-
all rate of side effects as well as the frequency of specific
side effects such as dry mouth, dizziness, drowsiness,
headache,insomnia,rash or itching,blurred vision,diar-
rhea,and weight loss when compared with the actual rate
reported by their patients.That clinicians underestimate
the prevalence of side effects likely contributes to inad-
equate communication before and during prescription of
antidepressants.
The impact of side effects on achieving depressive remis-
sion and on therapy adherence is great. In a study by
Demyttenaere et al
3 of 272 outpatients receiving antide-
pressant therapy,53% had discontinued treatment by the
end of the 6-month study.Of these patients,23% cited
“adverse events”as the reason for their discontinuation.
In a similar study,Hu et al
1 found that 33% of patients
had discontinued their treatment by the end of a 105-day
period,with the most often-cited reason being adverse
effects (36%).This study found that the presence of mul-
tiple side effects or the presence of side effects deemed
extremely bothersome by patients significantly increased
the odds of discontinuation.In addition to disrupting the
goal of achieving a minimally adequate course of antide-
pressant treatment for achieving remission and prevent-
ing relapse and recurrence,side effects frequently impede
adequate dose titration, necessary for delivering a full
therapeutic dose.Although precise estimates are difficult
to find,it is a frequent clinical observation that patients
struggling with side effects often remain on lower-than-
optimal doses for long periods of time,during which their
depression is inadequately treated.In addition,bother-
some side effects such as somnolence or sexual dysfunc-
tion,even when they do not lead to premature drug dis-
continuation or inadequate dosing,clearly compromise
quality of life.
Methodological issues
There are considerable methodological challenges
related to the study and clinical management of side
effects.When evaluating side-effect data,it is important
to consider whether the information was obtained by
spontaneous report,self-report checklists,or responses
to direct questioning. Spontaneous reporting of side
effects following an open-ended question (eg, “any
change since last visit?”) typically yields a lower inci-
dence of adverse events than itemized self-report check-
lists (eg, the Frequency, Intensity, and Burden of Side
Effects Rating (FIBSER) Scale
4) or direct questioning
about specific side effects (The Systematic Assessment
for Treatment Emergent Events-Specific Inquiry [SAF-
TEE-SI]
5).The reporting of certain side effects,particu-
larly sexual dysfunction,may also be influenced by the
degree of comfort the patient/subject has with the sub-
ject area and with the questioner;this may be affected by
gender,culture,and other factors.Side-effect rates pre-
sented for an antidepressant in isolation tend to be of
somewhat limited benefit,as common experiences such
as headache or rhinitis inevitably figure prominently,
even if they bear no specific relationship to the agent.
Hence,side effects presented as placebo-adjusted rates
are often more informative.So too are comparative rates
of specific side effects across a number of antidepressant
agents, which allow clinicians and patients to make
informed choices about the relative risks of side effects
of greatest concern to the patient.
In both research and clinical contexts,an important chal-
lenge is presented by the phenomenological overlap
between side effects and residual symptoms of depres-
sion.Thus,fatigue,cognitive impairment,apathy,jitteri-
ness and irritability,and sleep and appetite changes are
core features of depression,but may also be related to
antidepressant treatment. In a small study of 43
depressed inpatients,
6 which investigated the rate of
somatic symptoms and complaints that were present
before and after treatment,many symptoms often con-
sidered to be side effects of drugs were also present prior
to treatment, including dry mouth, lightheadedness,
sweating, tremors, and constipation. The distinction
between residual symptoms and side effects is crucial,as
they call for very different responses.In the latter case,a
dose increase or pharmacological or other augmentation
of treatment may be required.In the former case,a dose
reduction or use of a pharmacological antidote would be
important initial considerations.A careful delineation of
depressive symptoms prior to the initiation of antidepres-
sant treatment,such as with the use of a structured rat-
ing scale such as the Inventory for Depressive
Symptomatology,
7 is particularly helpful as a supplement
to clinical judgment to determine which adverse events
are truly treatment-emergent and which may reflect per-
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Conversely,in some instances,an experience recorded as
an adverse event may have been related to depressive
improvement; this is particularly true in an individual
whose increased weight following a period of anorexia
related to depression might be more accurately con-
strued as normalization than weight gain.
An additional, frequently overlooked factor that may
confound interpretation of apparent adverse events has
to do with discontinuation-emergent effects of antide-
pressants,which can resemble antidepressant side effects
and/or residual symptoms.Thus,for example,a patient
with intermittent noncompliance on antidepressants such
as venlafaxine or paroxetine that are associated with
common discontinuation-related syndromes may expe-
rience malaise or nausea after a day or two off medica-
tion without being aware of their relationship to abrupt
drug discontinuation.Fortunately,when patient history
raises the possibility that apparent side effects or resid-
ual symptoms are attributable to inconsistent dosing,the
hypothesis can be simply tested if the patient is willing to
commit to more regular dosing.In the case of forgetful
patients, daily pillboxes or newer technologies such as
electronic caps that remind the patient of skipped doses
are often helpful.In other patients,education about dis-
continuation effects and/or efforts to address possible
ambivalence about use of medications may reduce
instances of medication cessation.
Side effects most likely to cause 
drug discontinuation
An understanding of which side effects occur most fre-
quently and which of these are most likely to lead to
patient nonadherence enhances one’s ability to choose a
drug and counsel patients.The most common side effects
reported by patients in the study by Hu et al
1 of 401 out-
patients taking SSRIs were drowsiness (38%),dry mouth
(34%),and sexual dysfunction (34%).This study,which
was conducted in 1999-2000,questioned patients about
side effects via phone interviews within 75 to 105 days of
starting antidepressant therapy.The side effects deemed
most bothersome were sexual dysfunction (17%),
drowsiness (17%),and weight gain (11%).While these
were the were the most common, Lin et al
8 looked at
which side effects were most likely to lead to discontin-
uation in their naturalistic study of 155 outpatients on
antidepressant therapy (a tricylic antidepressant, tra-
zodone,or fluoxetine).They found that severe daytime
sleepiness showed a significant association with early dis-
continuation, and if experienced to a degree deemed
severe by patients,fatigue,blurred vision,insomnia,anx-
iety,appetite changes,and weight gain were all signifi-
cantly associated with discontinuation in months two and
three of treatment.
Time period of side effects
To further understand side effects and their impact on
patients’ quality of life and compliance,it is also impor-
tant to be aware of the time when certain side effects pre-
sent.While there is common belief that side effects can
be classified as acute or chronic,a review by Papakostas
9
challenged this idea.In it,he cites Hu et al’s
1 study that
shows that although certain side effects may present
early or later in the course of treatment,many of those
that are considered acute persist to a point that they
should be considered chronic.In this study,SSRI-induced
side effects such as insomnia, sexual dysfunction, and
drowsiness that are often considered acute persisted at 3
months. On the other hand, some side effects such as
nausea do start early in the course of treatment and then
usually improve,while others such as weight gain are not
present initially but emerge over time.Another natural-
istic study by Demyttenaere et al
3 of 272 outpatients on
an SSRI,trazodone,venlafaxine,or moclobemide looked
at the time period that patients discontinue treatment
secondary to side effects, and found that patients who
cited side effects as their reason for discontinuation
dropped out of treatment at a mean period of 6.5 weeks.
This study showed that side effects and lack of efficacy
led to the earliest discontinuation of antidepressants (at
6.5 weeks and 7 weeks respectively),followed by other
reasons such as “fear of drug dependence”and “feeling
better”that occurred at 8 weeks and later.Reinforcing
the conclusion that side effects often account for early
discontinuation,Bull et al
10 found that significantly more
patients discontinued or switched their SSRI because of
an adverse effect within the first 3 months of treatment
compared with the second 3 months.
Side effects as predictors of response
Although there are no systematic studies to our knowl-
edge that address specific treatment-emergent adverse
effects as predictors of response,we are aware that opti-
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effects,such as activation or insomnia,as favorable prog-
nosticators.Emerging biomarkers,such as quantitative
electroencephalography
11 or neuroimaging,
12 alone or in
conjunction with clinical features at baseline and during
treatment, represent an important area of current
research.Nevertheless,while the presence of particular
side effects has no known prognostic significance,when
patients have no side effects and minimal response
despite full doses of an antidepressant,it is reasonable to
re-evaluate medication adherence as well as to consider
the possibility of drug-drug interactions (particularly
metabolic induction) and genetic polymorphism that
might call for higher doses to achieve an optimal out-
come.
Common side effects and their management
Given the impact of side effects on treatment adherence,
response, and quality of life, an understanding of the
management of common side effects is imperative for
optimal management of depressed outpatients.
Successful management of side effects enhances adher-
ence,permits adequate dosing,improves patient comfort
and function,and prevents premature discontinuation of
therapy.Appropriate management includes thoughtful
drug selection,the anticipation of common and rare but
serious side effects with patients,and striving for the low-
est effective dose and simplest drug regimens consistent
with appropriately vigorous treatment.It also includes
the addition of appropriate adjunctive therapies to man-
age emergent complaints.
Fatigue and somnolence
Fatigue or drowsiness is a common side effect experi-
enced by 10% to 38% of antidepressant-treated outpa-
tients.
1,13 In one study of 401 outpatients,
1 70% of people
who experienced fatigue had it by 2 weeks,and 63% con-
tinued to experience it at 3 months.In comparative stud-
ies, SSRIs had a higher rate of sleepiness than bupro-
pion
14 and the noradrenergic reuptake inhibitor,
reboxetine,
15 and equivalent rates as nefazodone,
16-18 ven-
lafaxine,
19-21 and duloxetine
22-23 and the reversible
monoamine oxidase inhibitor moclobemide.
24
Mirtazapine
25 and trazodone
26 are associated with greater
rates of somnolence and fatigue than SSRIs.The differ-
ential of drowsiness should include residual symptoms of
depression,a primary sleep disorder such as obstructive
sleep apnea or restless leg syndrome or altered sleep
cycle, and substance-use disorders. Management of
drowsiness includes careful evaluation of sleep patterns
and counseling on sleep hygiene measures (such as
avoidance of daytime napping),changes in antidepres-
sant dosing schedule such as a shift from morning to
nighttime administration, divided dosing or use of a
slower release preparation,as well as pharmacological
management with psychostimulants,modafinil,bupro-
pion, reboxetine, or protriptyline, or consideration of
alternative remedies such as methylfolate or S-adenosyl-
methionine.For some patients,a graduated increase in
exercise may also help reduce fatigue.
Sexual dysfunction
Sexual dysfunction is a common long-term problem on
antidepressants.Medication side effects typically affect
libido,arousal,orgasm,and ejaculation,
27 and may affect
lubrication and erection.These side effects have tradi-
tionally been greatly underreported,largely related to
patients’ and clinicians’ reticence to address this topic.In
a study of 344 patients by Montejo-Gonzalez et al,
28 58%
of patients reported sexual dysfunction when physicians
directly inquired,compared with only 14% of those who
spontaneously reported sexual dysfunction.In a natural-
istic study that directly inquired about side effects
through closed-ended questions,
1 34% of patients
reported sexual dysfunction,with half of these patients
(17% of the overall group) deeming it bothersome.
Seventy percent of patients who experienced sexual dys-
function did so by 2 weeks,with 80% experiencing it at 3
months.
There are clear differences among antidepressant agents
in rates of sexual dysfunction. Bupropion immediate-
release and nefazodone were found to have the lowest
rate of sexual dysfunction in a study of more than 6000
individuals on SSRIs, bupropion, mirtazapine, nefa-
zodone,reboxetine,and venlafaxine.
29 Studies comparing
SSRIs with mirtazapine are inconclusive,some showing
higher rates of sexual dysfunction with SSRIs and others
with mirtazpine.
30-35 Among the SSRIs, paroxetine has
been found to have the highest rates of sexual dysfunc-
tion.
35
Management of sexual dysfunction,like all side effects,
begins with a thorough assessment during the initial
evaluation to establish a baseline, including discussion
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of satisfaction with sexual function prior to treatment,
and to discuss concerns about possible sexual dysfunc-
tion related to anticipated treatment.It is important to
reassess sexual function periodically during the course
of therapy, and also to recognize that sexual function
may become increasingly important to patients as their
depressive symptoms improve.
36 Prior to the introduc-
tion of sildenafil and similar agents,many methods and
medications were used in an attempt to treat the sexual
side effects of antidepressants. These included dose
reduction, timing of sexual activity toward the end of
a dosing interval,several days' drug holiday,
37 and anti-
dote therapy with medicine such as psychostimulants
38
and dopamine (DA) agonists such as amantadine,
pramipexole and Dexedrine,norepinephrine (NE)/DA
agents such as bupropion, serotonin (5-HT)2 receptor
antagonists such as nefazodone, and α2-adrenergic
receptor antagonists such as yohimbine.
39-40As sildenafil
has proven effective in placebo-controlled trials in the
treatment of sexual performance,
41 this agent and
related phosphdiesterase V inhibitors have become the
mainstay of management of sexual function.A recent
trial
42 also demonstrated that sildenafil is effective 
at decreasing adverse sexual effects in women taking
SSRIs,including improvement in desire,arousal-sensa-
tion, arousal-lubrication, orgasm, and enjoyment.
Nevertheless,many patients do not respond sufficiently
well to sildenafil and related agents or other attempted
antidotes, and efforts to identify other remedies con-
tinue. These include complementary and alternative
treatments such as maca root,arginine-containing com-
pounds, and ginkgo biloba.When sexual dysfunction
persists despite efforts at dose adjustments and antidote
therapy,the principal option is to consider switching to
agents with lesser degrees of sexual dysfunction, typi-
cally bupropion, or, where available, reboxetine.
Nefazodone is another option, though its use has been
limited by risk of rare but serious hepatotoxicity.
Gastrointestinal problems
Nausea and stomach upset
Nausea and stomach upset are also common side effects
of antidepressant treatment, present in 17% to 26% of
patients taking it,
1,13 83% of whom experienced it by 2
weeks,and 32 % of whom continued to experience it at
3 months.Treatment with SSRIs was associated with a
higher rate of nausea than bupropion,
43 moclobemide,
24
mirtazapine,
25 and reboxetine.
15 Equivalent rates were
found between SSRIs and trazodone,
26,44 nefazodone,
16-
18 and duloxetine.
22-23Venlafaxine has been found to have
a higher incidence of nausea than SSRIs.
9 Some studies
have found that nausea from venlafaxine and paroxe-
tine may be reduced using controlled-release formula-
tions.
45 The management of nausea and vomiting
includes the use of divided dosing or taking medications
with a small amount of food, such as crackers or toast.
Some patients benefit from ginger-containing foods and
beverages, histamine 2 antagonists such as ranitidine,
46
or proton pump inhibitors such as omeprazole.
Adjunctive promethazine, prochlorperazine, or
ondansetron also have been shown to be beneficial, as
has mirtazepine because of its 5-HT3 receptor antago-
nistic properties.
Diarrhea
Diarrhea may also occur as a side effect of antidepres-
sant treatment.As with the other gastrointestinal side
effects of antidepressants,it may be a transient effect and
resolve within weeks, but it also may persist in some
patients.A meta-analysis of 84 trials
13 found that overall,
16% of patients taking SSRIs experienced diarrhea.Hu
et al
1 found a rate of 15% of patients who experienced
diarrhea, 78% of whom experienced it at 2 weeks and
45% of whom still experienced it at 3 months.
Management of diarrhea can include antidiarrheal agents
such as loperamide, or diphenoxylate hydrochloride.
Cyproheptadine,Lactobacillus acidophilus culture,and
psyllium may also be helpful.
Constipation
Constipation may emerge during antidepressant therapy.
Of the SSRIs, paroxetine has been associated with the
highest rates of constipation,presumably secondary to its
high affinity for muscarinic receptors.
47 Overall,the rate
of constipation has been found to be 11% to 12.5%,
1,13
with 4.7% of patients describing it as a bothersome side
effect.
1 Constipation can often be controlled with ade-
quate activity,fluid,and fiber intake.When pharmacolog-
ical management is required, bulk-forming laxatives,
stool softeners, osmotic agents, bethanechol, and
cholinesterase inhibitors may be used.
46
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Another bothersome effect of antidepressant treatment
that may interfere with treatment adherence and gen-
eral health is weight gain.This is also an effect that is
often difficult to study because it can be a sign of
improvement in patients who have weight loss as a
symptom of depression,a residual symptom in patients
who overeat when depressed, or something indepen-
dent of depression or its treatment.For this reason,it is
important to look at placebo rates of weight gain when
evaluating these rates in patients. There are various
ways that weight gain is studied and reported,including
as the percentage of weight gain from baseline or as
rate of weight gain greater than 7% from baseline.
Although complaints of weight gain often emerge late
in treatment, there are relatively few studies that have
systematically assessed this side effect on long-term
treatment and fewer that have had the opportunity to
compare weight gain on active treatment with that on
placebo.
48 Many of the long-term studies show no dif-
ference between SSRIs and placebo, except for parox-
etine,showing a significant difference from placebo.
49,50
There was no drug/placebo difference in weight gain in
a study looking at fluoxetine over 26 weeks of continu-
ation treatment
51 or in a 6-month duration study of
citalopram.
52 In a study comparing the rate of weight
gain on antidepressants,
9 mirtazapine was associated
with the highest percentage of patients with weight gain
(26%), followed by SSRIs and venlafaxine (16% to
19%). Nefazodone,
53 bupropion,
54 and reboxetine
55
result in the lowest rates of weight gain during treat-
ment.Among tricyclic antidepressants, the secondary
amine tricyclics,such as desipramine,nortriptyline,and
protriptyline,have generally been associated with lower
weight gain than the tertiary amine agents such as
imipramine, amitriptyline, and clomipramine.
The management of antidepressant-associated weight gain
is challenging and should begin with the choice of drug.
Clinicians should try to identify patients who are at risk for
weight gain based on medical history and lifestyle, and
these patients should be targeted for dietary and physical
activity interventions.The addition of bupropion,topira-
mate,zonisamide,or sibutramine may also be considered.
As weight gain may not be dose-dependent,at least within
the therapeutic range of doses,a modest dose reduction is
often ineffective.In the setting of unacceptable weight gain
that is not responsive to dietary and behavioral modifica-
tions, a switch to an agent with a lower propensity for
weight gain is a primary consideration.
Insomnia
Rates of insomnia have been found to be 12% to 22%
(antidepressants administered to outpatients with MDD,
enrolled in clinical trials who report insomnia as a treat-
ment emergent side effect),
1,13 with 11% of patients deem-
ing it bothersome.Sixty-four percent of patients who expe-
rienced insomnia experienced it by 2 weeks, and 56%
continued to experience it at 3 months.
1 In a review of anti-
depressant-induced side effects,Papakostas
9 cites higher
rates of insomnia with SSRIs than with mirtazapine,tra-
zodone, and nefazodone, and equivalent rates between
SSRIs and bupropion,moclobemide,duloxetine,and ven-
lafaxine.Reboxetine was found to have a higher rate of
insomnia than SSRIs.It is particularly important to rule
out primary sleep disorders or concomitant alcohol and
other substance abuse when evaluating and managing
insomnia.Management of antidepressant-induced insom-
nia includes educating patients on behavior techniques
and sleep hygiene, modification of use of caffeine and
common sympathomimetic agents,changing the timing of
doses,and adding adjunctive medications including spar-
ing use of benzodiazepines,zolpidem,eszopiclone,mela-
tonin,trazodone,mirtazapine,and/or low doses of anticon-
vulsants,and atypical antipsychotics.
Tremor
Fine and rapid tremors of the extremities can occur as a
side effect of antidepressants.Rates of tremor of SSRIs
and venlafaxine are 3 to 5 times higher than placebo,
whereas the rate of tremor in nefazodone and mirtazap-
ine therapy is only 2 to 2.5 times higher than placebo.
56 It
is important to consider other agents or causes when
assessing a tremor,including caffeine intake and anxiety
as well as common antidepressant adjuncts such as the
atypical antipsychotics.Decreasing caffeine intake and
the use of benzodiazepines and β-blockers can be help-
ful in the treatment of tremor.
Apathy
The development of apathy or indifference can be a
bothersome side effect associated with antidepressant
medication.Symptoms that can include amotivation or
Translational research
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dullness often develop slowly,and although the mecha-
nism of this effect is unclear,it may be secondary to an
inhibition of dopamine by serotonergic medications.
57
Apathy is a challenging and elusive complaint to evalu-
ate and may be secondary to drug treatment,a residual
symptom, or may herald relapse. Some, but not all,
patients are able to point to a distinction between the
comfortable detachment they feel when experiencing
antidepressant-related apathy in the setting of an other-
wise satisfactory response to treatment compared with
the more anguished or far-reaching anhedonia and moti-
vational impairment they experience when depressed.If
a relapse or residual symptoms are not suspected,man-
agement strategies include dose reduction,switching to
a different drug or class,typically toward less serotoner-
gic agents,or the addition of a stimulant or dopaminer-
gic drug.Pharmacologic options include methylphenidate
or dextroamphetamine,bupropion,amantadine,ropini-
role,pramipexole,modafinil,or pergolide.
Discontinuation syndrome
Abrupt discontinuation of SSRIs,nefazodone,venlafax-
ine,and mirtazapine may precipitate a discontinuation
syndrome that can occur hours to days following the ter-
mination of medication.The syndrome often includes flu-
like symptoms such as malaise,myalgias,nausea,dizzi-
ness, and headache, and may even include neurologic
symptoms such as unsteady gait, dysesthesias such as
unusual shock-like sensations,tremulousness,or vertigo.
46
Risk factors for discontinuation syndrome include abrupt
cessation of short-acting agents and/or agents at a high
dose. Indeed, in some patients, some of the features of
discontinuation syndrome simply from an abrupt dose
reduction rather than actual cessation. As previously
noted in this review,discontinuation symptoms may mas-
querade as side effects of treatment.Discontinuation syn-
drome may be minimized with the use of a gradual taper
schedule.Patient education about the risk of discontinu-
ation symptoms is crucial whenever an antidepressant
likely to be associated with discontinuation emergent
symptoms is prescribed.Substituting a longer-acting anti-
depressant,most notably fluoxetine,for a shorter-acting
one may also decrease the risk of withdrawal syndrome.
58
This is particularly helpful for patients who have already
demonstrated problems tapering another antidepressant
because of discontinuation emergent adverse events.The
addition of benzodiazepines for irritability, anxiety, or
sleep disturbance related to discontinuation or nons-
teroidal anti-inflammatory agents for pain may improve
patient experience.Communication with patients about
the short duration of withdrawal symptoms may help
patients cope with these typically self-limited symptoms.
Other management techniques for 
preventing relapse or discontinuation 
due to side effects
Patient education
A critical component to side-effect management is edu-
cation of patients prior to prescribing an antidepressant.
This should include discussion of common side effects
and when they would be most likely to emerge. It is
important to discuss with patients which side effects
require a prompt evaluation (eg,rash,agitation,worsen-
ing suicidality) and which side effects are likely to be self-
limiting (eg, mild nausea or jitteriness). Patients may
assign a different value to certain side effects than their
clinician;given the large number of agents available it is
important to reach agreement on how the anticipated
risks and benefits of treatment will factor into choice of
agent.Patients may harbor certain preconceptions about
side effects which can be addressed at this time.
Examples of this would include the mistaken belief that
side effects necessarily indicate toxicity or indicate that
the medication is a poor match for the patient.It is often
helpful to let patients know that antidepressants are asso-
ciated with a range of side effects that typically do not
indicate a safety concern nor predict poor response.
Patients are often reassured also to learn about the avail-
ability of strategies to address most side effects including
dose changes,pharmacological antidotes,and the option
to switch to other medications.
Some clinicians are reluctant to discuss side effects in
advance because of a concern that it will make patients
anxious and may magnify side effect concerns.The liter-
ature offers some support of this in a naturalistic study
showing that patients who recalled being informed of
potential adverse events by their physicians were 55%
more likely to report experiencing mild or moderate
adverse effects.
10 Although these patients were more
likely to report side effects,this same study,as well as a
naturalistic study done by Bull et al,
2 found that dis-
cussing adverse effects with patients during treatment
was associated with the same or less premature discon-Translational research
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tinuation and with a higher rate of switching medications.
Switching medications in this instance may represent a
positive alternative to discontinuing treatment.
Nondrug therapy
Other successful techniques that have been shown to
improve patient adherence to medication include the use
of cognitive behavioral therapy and the participation in
other concurrent nondrug therapy,
10 particularly when
care is closely coordinated between the clinician prescrib-
ing medication and the clinician providing psychother-
apy when these roles are separate. In another area of
medical treatment, Safren et al
59,60 have shown that in
HIV-positive patients,an intervention called Life-Steps,
which is a single-session intervention utilizing cognitive-
behavioral,motivational interviewing,and problem-solv-
ing techniques,improves adherence to HIV antiretrovi-
ral therapy.Further study should be directed at specific
psychotherapeutic interventions similar to these that sup-
port treatment adherence in the pharmacotherapy of
depression.
Conclusion
Antidepressant side effects are a common clinical chal-
lenge,often jeopardizing treatment adherence and quality
of life.Physicians may underestimate the prevalence of side
effects and may be reticent to address them proactively out
of a mistaken concern that their impact will be magnified.
The successful management of side effects begins with ade-
quate communication and patient education prior to and
throughout treatment with antidepressants.In addition,it
involves thoughtful differentiation of treatment-emergent
side effects from residual depressive symptoms,relapse and
recurrence, discontinuation related adverse events, and
intercurrent general medical problems. Finally, optimal
management of side effects involves drawing upon a full
array of strategies including dose reduction,changes in the
timing of doses or the drug preparation,behavioral strate-
gies,pharmacological antidotes,and willingness to consider
switching to other agents.Sound and resourceful manage-
ment of side effects is an important component in achiev-
ing depressive remission and enhancing patient safety and
quality of life. ❏
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Buscando la respuesta óptima: comprensión
y manejo de los efectos secundarios de los
antidepresivos
En las últimas dos décadas la seguridad y tolerabili-
dad de los antidepresivos ha mejorado considerable-
mente. Sin embargo, todavía los efectos secundarios
de los antidepresivos son frecuentes y problemáticos.
La mayoría de los pacientes tratados con los medica-
mentos actuales experimentan uno o más efectos
secundarios significativos. Estos efectos secundarios a
menudo crean barreras para alcanzar la remisión de
la depresión, al igual que para prevenir recaídas y
recurrencias.  Los clínicos tienden a subestimar la pre-
valencia de efectos secundarios y hasta un cuarto de
los pacientes discontinúa los antidepresivos por tole-
rar mal dichos efectos; otros pueden continuar la
terapia antidepresiva, pero experimentan una dismi-
nución en la calidad de vida relacionada con los
molestos efectos secundarios. Este artículo revisa la
prevalencia de efectos secundarios, el impacto de
ellos en la adherencia al tratamiento y temas meto-
dológicos que incluyen el desafío de distinguir los
efectos secundarios de los síntomas depresivos resi-
duales, los efectos de la discontinuación y problemas
médicos generales. Además se hace referencia a los
efectos secundarios más comunes como la disfunción
sexual, problemas gastrointestinales, alteraciones del
sueño, apatía y fatiga, y se ofrecen estrategias para
el manejo que pueden ayudar a los pacientes a obte-
ner una respuesta óptima a la farmacoterapia. 
Vers une réponse optimale : compréhension
et prise en charge des effets secondaires des
antidépresseurs
L’innocuité et la tolérance des antidépresseurs ont été
considérablement améliorées au cours de ces vingt
dernières années. Leurs effets secondaires restent
néanmoins courants et source de problèmes. La plu-
part des patients traités par les molécules actuelles
souffrent d’un ou plusieurs effets secondaires
gênants. Ceux-ci empêchent souvent l’obtention
d’une rémission de la dépression ou de la prévention
d’une récidive ou d’une rechute. Les médecins ont
tendance à sous-estimer la prévalence des effets
secondaires et jusqu’à un quart des patients arrêtent
leur traitement antidépresseur car ils ne tolèrent pas
ces effets gênants ; les autres continuent leur traite-
ment mais leur qualité de vie en est diminuée. Cet
article passe en revue la prévalence des effets secon-
daires, leur impact sur l’observance du traitement et
les questions méthodologiques comme celle de dis-
tinguer les effets secondaires des symptômes dépres-
sifs résiduels, des effets dus à l’interruption du traite-
ment et des affections médicales  générales. De plus,
nous abordons les effets secondaires les plus courants
comme les troubles sexuels, gastro-intestinaux, les
perturbations du sommeil, l’apathie et la fatigue et
nous proposons des stratégies de prise en charge afin
d’aider les patients à obtenir une réponse optimale
au traitement médicamenteux.
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